---
title: "Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002393.SZ.md"
symbol: "002393.SZ"
name: "Tianjin Lisheng Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T23:06:24.709Z"
locales:
  - [en](https://longbridge.com/en/quote/002393.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002393.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002393.SZ.md)
---

# Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)

## Company Overview

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets, and Youhao Maren soft capsules.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.lishengpharma.com](https://www.lishengpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.44)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 134 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.99% |  |
| Net Profit YoY | 128.56% |  |
| P/B Ratio | 1.05 |  |
| Dividend Ratio | 4.79% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4831509970.82 |  |
| Revenue | 1356865680.25 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.78% | B |
| Profit Margin | 30.48% | A |
| Gross Margin | 55.32% | B |
| Revenue YoY | 0.99% | C |
| Net Profit YoY | 128.56% | A |
| Total Assets YoY | -4.21% | D |
| Net Assets YoY | -3.93% | D |
| Cash Flow Margin | 60.42% | C |
| OCF YoY | 0.99% | C |
| Turnover | 0.24 | D |
| Gearing Ratio | 16.15% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tianjin Lisheng Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.99%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "128.56%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.05",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.79%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4831509970.82",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1356865680.25",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.78%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "30.48%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "55.32%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "0.99%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "128.56%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.21%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.93%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "60.42%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.99%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.24",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.15%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 11.55 | 3/215 | 27.52 | 14.64 | 14.11 |
| PB | 1.04 | 9/215 | 1.28 | 1.14 | 1.07 |
| PS (TTM) | 3.52 | 95/215 | 4.57 | 4.28 | 3.90 |
| Dividend Yield | 4.85% | 11/215 | 2.85% | 1.65% | 1.47% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002393.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002393.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002393.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002393.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**